Clinical Study of BRL-101 in Severe SCD

Key facts

Sponsor

Bioray Laboratories

Principal Investigator

Yongrong Lai, phD

First Affiliated Hospital of Guangxi Medical University

Intervention

BRL-101(drug)

Enrollment

3 enrolled

Eligibility

3-35 years · All sexes

Timeline

2024 – 2026

Study locations (1)

• First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Collaborators

First Affiliated Hospital of Guangxi Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Sickle cell disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE4NCT06979492
  Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
  Emory University
• RECRUITINGNCT07392216
  Functional Ovarian Reserve in Sickle Cell Disease
  St. Jude Children's Research Hospital
• RECRUITINGNANCT07246265
  Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care
  University Hospital, Tours
• ENROLLING BY INVITATIONPHASE2NCT07401823
  Open-Label Extension Study to Pioneer Study 6058-SCD-101
  Fulcrum Therapeutics
• RECRUITINGPHASE1, PHASE2NCT07432867
  Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGNANCT07222475
  Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease
  Mayo Clinic
• RECRUITINGPHASE2NCT07224360
  Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
  CSL Behring
• RECRUITINGPHASE3NCT07247188
  Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
  Sanofi

See all trials for Sickle cell disease →